# Allink Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allink-biotherapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: http://en.allinkbio.com/
- Total disclosed funding: $89M
- Latest round: Series A (Dec 16, 2025)
- Investors on record: 10

## About

Established in 2023 and based in Shanghai, China, Allink Biotherapeutics operates as a biopharmaceutical company that focuses on the research and development of innovative drugs. The founder and CEO of the company, Hui Feng graduated from the Albert Einstein College of Medicine of Yeshiva University. In December 2025, Allink Biotherapeutics raised USD 47 million in series A funding co-led by returning investor Legend Capital and new investor Meituan, Inc., with participation from other new investors 5Y Capital, Lapam Capital and Runzhang Investment. Returning investors Lanchi Ventures, YuanBio Venture and other unspecified investors also participated in the round.

The company mainly provides innovative drugs. Its core pipeline is ALK201 and ALK202, which are mainly used in the field of tumour treatment. Allink Biotherapeutics has also developed a bispecific antibody product pipeline and antibody-drug conjugates (ADCs). Bispecific antibodies are mainly targeted at tumours and immune diseases.

The company will use the December 2025 funding to advance global Phase I trials for two ADC programs and develop multi-specific antibody platforms.

## Funding rounds

- Series A, Dec 16, 2025, $47M — Legend Capital, 5Y Capital, YuanBio Venture, Meituan, Inc., Lapam Capital, Runzhang Investment, Lanchi Ventures
- Series A, Nov 28, 2024, $42M — Legend Capital, Gaorong Ventures, YuanBio Venture, Lanchi Ventures, MED-FINE Capital, Xiamen C&D Emerging Industry Equity Investment

## Investors

- Legend Capital — Series A
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Lanchi Ventures (https://capitalatlas.ai/funds/lanchi-ventures) — Series A
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series A
- Xiamen C&D Emerging Industry Equity Investment (https://capitalatlas.ai/funds/xiamen-c-d-emerging-industry-equity-investment) — Series A
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A
- Meituan, Inc. — Series A
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A
- Runzhang Investment (https://capitalatlas.ai/funds/runzhang-investment) — Series A